Bicocca Open Archive

Logo unimib boa
GEETA, GEETA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.565
AS - Asia 1.438
EU - Europa 1.303
SA - Sud America 195
AF - Africa 47
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 5.560
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.506
SG - Singapore 480
CN - Cina 341
IT - Italia 316
DE - Germania 253
HK - Hong Kong 185
VN - Vietnam 170
RU - Federazione Russa 162
BR - Brasile 149
SE - Svezia 112
IE - Irlanda 105
GB - Regno Unito 78
FR - Francia 71
PL - Polonia 54
IN - India 53
CA - Canada 38
ID - Indonesia 34
UA - Ucraina 30
BD - Bangladesh 29
ES - Italia 23
TR - Turchia 23
FI - Finlandia 21
JP - Giappone 20
NL - Olanda 17
KR - Corea 16
ZA - Sudafrica 15
BE - Belgio 14
AR - Argentina 13
DK - Danimarca 12
MX - Messico 12
SA - Arabia Saudita 10
AT - Austria 9
IR - Iran 8
UZ - Uzbekistan 8
VE - Venezuela 8
CH - Svizzera 7
EC - Ecuador 7
MA - Marocco 7
MY - Malesia 7
PK - Pakistan 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
CO - Colombia 6
IQ - Iraq 6
PE - Perù 6
DZ - Algeria 5
GR - Grecia 5
JO - Giordania 5
KE - Kenya 5
TN - Tunisia 5
CL - Cile 4
CR - Costa Rica 4
EU - Europa 4
NP - Nepal 4
OM - Oman 4
TW - Taiwan 4
IL - Israele 3
NO - Norvegia 3
RO - Romania 3
EG - Egitto 2
GE - Georgia 2
KG - Kirghizistan 2
KW - Kuwait 2
LT - Lituania 2
PH - Filippine 2
SO - Somalia 2
TH - Thailandia 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GH - Ghana 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
LB - Libano 1
LY - Libia 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SC - Seychelles 1
SN - Senegal 1
TO - Tonga 1
UY - Uruguay 1
Totale 5.560
Salva come PNG Salva come JPEG
Città #
Ann Arbor 673
Singapore 267
Ashburn 222
Frankfurt am Main 191
Hong Kong 174
San Jose 166
Milan 127
Chandler 124
Wilmington 118
Fairfield 107
Dublin 104
New York 71
Los Angeles 66
Woodbridge 56
The Dalles 53
Beijing 51
Hanoi 49
Ho Chi Minh City 49
Houston 44
Seattle 44
Dallas 42
Dearborn 42
Lodz 36
Cambridge 33
Santa Clara 33
Chicago 30
Jakarta 30
Princeton 30
Shanghai 25
Council Bluffs 22
Munich 20
Buffalo 19
Lauterbourg 18
Hefei 17
Nanjing 16
Moscow 15
Seoul 15
Brussels 14
Da Nang 14
Lawrence 14
São Paulo 14
Fremont 13
Phoenix 13
Warsaw 13
Johannesburg 12
Toronto 12
Changsha 11
London 11
Orem 11
Tokyo 11
Altamura 10
Hangzhou 10
Jacksonville 10
Ottawa 10
Helsinki 9
Rio de Janeiro 9
Guangzhou 8
Haiphong 8
Nuremberg 8
Turku 8
Andover 7
Dhaka 7
Istanbul 7
Jinan 7
Norwalk 7
San Diego 7
Stockholm 7
Amsterdam 6
Boston 6
Brooklyn 6
Columbus 6
Denver 6
Edmonton 6
Kent 6
Monza 6
Poplar 6
Shenyang 6
Tianjin 6
Amman 5
Atlanta 5
Campinas 5
Corsico 5
Erzurum 5
Hebei 5
Kiev 5
Montreal 5
Nairobi 5
Nanchang 5
Redmond 5
Romola 5
Tashkent 5
Zurich 5
Aylesbury 4
Barnet 4
Bergamo 4
Boardman 4
Cagliari 4
Casablanca 4
Chennai 4
Como 4
Totale 3.669
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 519
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 440
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 438
In vitro and in vivo characterization of resistance to lorlatinib treatment in ALK mutated cancers 392
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 387
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 361
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 359
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 327
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 294
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 282
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 279
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 279
We shall overcome (drug resistance) some day 265
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 264
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 262
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 221
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 220
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 186
Totale 5.775
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.556
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.556
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021123 0 0 0 0 0 0 0 0 0 0 59 64
2021/2022314 42 56 40 25 16 16 20 9 13 15 26 36
2022/2023567 53 150 72 51 45 76 7 35 22 39 9 8
2023/2024361 7 10 20 17 32 93 58 24 37 14 10 39
2024/2025988 50 74 33 50 116 52 82 33 126 157 82 133
2025/20262.026 227 104 217 228 239 127 371 93 178 200 42 0
Totale 5.775